Chronic fluoxetine treatment changes S100B expression during postnatal rat brain development

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 7, 2013, Pages 481-489

  Bock, Nathalie ^a   Koc, Emre ^a   Alter, Hannah ^a   Roessner, Veit ^b   Becker, Andreas ^a   Rothenberger, Aribert ^a   Manzke, Till ^a,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PROTEIN S100B;

ANIMAL EXPERIMENT; ARTICLE; BRAIN DEVELOPMENT; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DEVELOPMENTAL STAGE; FRONTAL CORTEX; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; POSTNATAL DEVELOPMENT; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANIMALS, NEWBORN; CORPUS STRIATUM; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; FRONTAL LOBE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HIPPOCAMPUS; MALE; RATS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SEROTONIN UPTAKE INHIBITORS;

EID: 84884509352     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0065     Document Type: Article

References (41)

1. Ahlemeyer B, Beier H, Semkova I, Schaper C, Krieglstein J: S-100beta protects cultured neurons against glutamate-and staurosporineinduced damage and is involved in the antiapoptotic action of the 5 HT(1A)-receptor agonist, Bay x 3702. Brain Res 858:121-128, 2000.
2. Andersen SL: Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 27:3-18, 2003.
3. Andersen SL, Navalta CP: New frontiers in developmental neuropharmacology: Can long-term therapeutic effects of drugs be optimized through carefully timed early intervention? J Child Psychol Psychiatry 52:476-503, 2011.
4. Ansorge MS, Morelli E, Gingrich JA: Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 28:199-207, 2008.
5. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA: Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306:879-881, 2004.
6. Azmitia EC, Dolan K, Whitaker-Azmitia PM: S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor. Brain Res 516:354-356, 1990.
7. Bell K, Shokrian D, Potenzieri C, Whitaker-Azmitia PM: Harm avoidance, anxiety, and response to novelty in the adolescent S-100beta transgenic mouse: role of serotonin and relevance to Down syndrome. Neuropsychopharmacology 28:1810-1816, 2003.
8. Blier P, de Montigny C: Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21:91S-98S, 1999.
9. Bock N, Alter H, Koc E, Roessner V, Rothenberger A, Manzke T: Chronic fluoxetine administration during different postnatal development stages leads to stage dependent changes of Glial Fibrillary Acidic Protein expression in rat brain. Br J Med Med Res 2:292-312, 2012.
10. Chang MS, Ariah LM, Marks A, Azmitia EC. Chronic gliosis induced by loss of S-100B: knockout mice have enhanced GFAPimmunoreactivity but blunted response to a serotonin challenge. Brain Res 1031:1-9, 2005.
11. Djalali S, Höltje M, Grosse G, Rothe T, Stroh T, Grosse J, Deng DR, Hellweg R, Grantyn R, Hörtnagl H, Ahnert-Hilger G: Effects of brainderived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J Neurochem 92:616-627, 2005.
12. Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60:540-551, 2003.
13. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 25:836-844, 2001.
14. Eriksen JL, Gillespie R, Druse MJ: Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Res Dev Brain Res 139:97-105, 2002.
15. Frey BN, Andreazza AC, Cereser KM, Martins MR, Petronilho FC, de Souza DF, Tramontina F, Goncalves CA, Quevedo J, Kapczinski F: Evidence of astrogliosis in rat hippocampus after d-amphetamine exposure. Prog Neuropsychopharmacol Biol Psychiatry 30:1231-1234, 2006.
16. Huttenlocher PR: Synaptic density in human frontal cortex-developmental changes and effects of aging. Brain Res 163:195-205, 1979.
17. Lidow MS, Goldman-Rakic PS, Rakic P: Synchronized overproduction of neurotransmitter receptors in diverse regions of the primate cerebral cortex. Proc Natl Acad Sci USA 88:10,218-10,221, 1991.
18. Liu JP, Lauder JM: S-100 beta and insulin-like growth factor-II differentially regulate growth of developing serotonin and dopamine neurons in vitro. J Neurosci Res 33:248-256, 1992.
19. Luo KR, Hong CJ, Liou YJ, Hou SJ, Huang YH, Tsai SJ. Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Prog Neuropsychopharmacol Biol Psychiatry 34:1433-1439, 2010.
20. Manev R, Uz T, Manev H. Fluoxetine increases the content of neurotrophic protein S100ß in the rat hippocampus. Eur J Pharamcol 420:R1-R2, 2001.
21. Mazer C, Muneyyirci J, Taheny K, Raio N, Borella A, Whitaker-Azmitia P: Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: a possible model of neurodevelopmental disorders with cognitive deficits. Brain Res 760:68-73, 1997.
22. Mito T, Becker LE: Developmental changes of S-100 protein and glial fibrillary acidic protein in the brain in Down syndrome. Exp Neurol 120:170-176, 1993.
23. Moll GH, Mehnert C, Wicker M, Bock N, Rothenberger A, Ruther E, Huether G: Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res Dev Brain Res 119:251-257, 2000.
24. Nishimura A, Ueda S, Takeuchi Y, Sawada T, Kawata M: Age-related decrease of serotonergic fibres and S-100 beta immunoreactivity in the rat dentate gyrus. Neuroreport 6:1445-1448, 1995.
25. Raponi E, Agenes F, Delphin C, Assard N, Baudier J, Legraverend C, Deloulme JC: S100B expression defines a state in which GFAPexpressing cells lose their neural stem cell potential and acquire a more mature developmental stage. Glia 55:165-177, 2007.
26. Reeves RH, Yao J, Crowley MR, Buck S, Zhang X, Yarowsky P, Gearhart JD, Hilt DC: Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proc Natl Acad Sci USA 91:5359-5363, 1994.
27. Richter-Landsberg C, Heinrich M: S-100 immunoreactivity in rat brain glial cultures is associated with both astrocytes and oligodendrocytes. J Neurosci Res 42:657-665, 1995.
28. Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI, Becker A, Rothenberger A, Bock N: Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the ADHD combined type, but not to the same extent in one of the ADHD inattentive type. Neurosci Behav Physiol 167:1183-1191, 2010.
29. Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S, Kirchner H: S-100B is increased in melancholic but not in nonmelancholic major depression. J Affect Disord 66:89-93, 2001.
30. Rothermundt M, Peters M, Prehn JH, Arolt V: S100B in brain damage and neurodegeneration. Microsc Res Tech 60:614-632, 2003.
31. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V: S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29:1004-1011, 2004.
32. Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E: Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 31:1164-1169, 2007.
33. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE: S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 13:1675-1678, 2002.
34. Schulte-Herbruggen O, Hortnagl H, Ponath G, Rothermundt M, Hellweg R: Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice. Neurosci Lett 442:100-103, 2008.
35. Shashoua VE, Hesse GW, Moore BW: Proteins of the brain extracellular fluid: Evidence for release of S-100 protein. J Neurochem 42:1536-1541, 1984.
36. Steiner J, Bernstein HG, Bogerts B, Gos T, Richter-Landsberg C, Wunderlich MT, Keilhoff G: S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivation. Neuroscience 154:496-503, 2008.
37. Teicher MH, Krenzel E, Thompson AP, Andersen SL: Dopamine receptor pruning during the peripubertal period is not attenuated by NMDA receptor antagonism in rat. Neurosci Lett 339:169-171, 2003.
38. Tramonita AC, Tramonita F, Bobermin LD, Zanotto C, Souza FD, Leite MC, Nardin P, Gottfried C, Gonçalves, CA: Serotonin of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 32:1580-1583, 2008.
39. Usala T, Clavenna A, Zuddas A, Bonati M: Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: A systematic review and metaanalysis. Eur Neuropsychopharmacol 18:62-73, 2008.
40. Whitaker-Azmitia PM, Murphy R, Azmitia EC: Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res. 528:155-158, 1990.
41. Yan W, Wilson CC, Haring J: 5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Res Dev Brain Res 98:185-190, 1997.